Intravenous leiomyomatosis

	WikiDoc Resources for Intravenous leiomyomatosis
Articles
Most recent articles on Intravenous leiomyomatosis Most cited articles on Intravenous leiomyomatosis Review articles on Intravenous leiomyomatosis Articles on Intravenous leiomyomatosis in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Intravenous leiomyomatosis Images of Intravenous leiomyomatosis Photos of Intravenous leiomyomatosis Podcasts & MP3s on Intravenous leiomyomatosis Videos on Intravenous leiomyomatosis
Evidence Based Medicine
Cochrane Collaboration on Intravenous leiomyomatosis Bandolier on Intravenous leiomyomatosis TRIP on Intravenous leiomyomatosis
Clinical Trials
Ongoing Trials on Intravenous leiomyomatosis at Clinical Trials.gov Trial results on Intravenous leiomyomatosis Clinical Trials on Intravenous leiomyomatosis at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Intravenous leiomyomatosis NICE Guidance on Intravenous leiomyomatosis NHS PRODIGY Guidance FDA on Intravenous leiomyomatosis CDC on Intravenous leiomyomatosis
Books
Books on Intravenous leiomyomatosis
News
Intravenous leiomyomatosis in the news Be alerted to news on Intravenous leiomyomatosis News trends on Intravenous leiomyomatosis
Commentary
Blogs on Intravenous leiomyomatosis
Definitions
Definitions of Intravenous leiomyomatosis
Patient Resources / Community
Patient resources on Intravenous leiomyomatosis Discussion groups on Intravenous leiomyomatosis Patient Handouts on Intravenous leiomyomatosis Directions to Hospitals Treating Intravenous leiomyomatosis Risk calculators and risk factors for Intravenous leiomyomatosis
Healthcare Provider Resources
Symptoms of Intravenous leiomyomatosis Causes & Risk Factors for Intravenous leiomyomatosis Diagnostic studies for Intravenous leiomyomatosis Treatment of Intravenous leiomyomatosis
Continuing Medical Education (CME)
CME Programs on Intravenous leiomyomatosis
International
Intravenous leiomyomatosis en Espanol Intravenous leiomyomatosis en Francais
Business
Intravenous leiomyomatosis in the Marketplace Patents on Intravenous leiomyomatosis
Experimental / Informatics
List of terms related to Intravenous leiomyomatosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Ammu Susheela, M.D. [3]

Synonyms and keywords: Nesidioblastoma, IVLM

Overview

Intravenous leiomyomatosis is characterized by the extension into venous channels of histologically benign smooth muscle tumor arising from either the wall of a vessel or from a uterine leiomyoma. The etiology of intravenous leiomyomatosis is unclear. Intravenous leiomyomatosis must be differentiated from other diseases such as renal malignancies and sarcoma. The median age is 45 years, with patients ranging from 26 to 70 years old. Only females may develop intravenous leiomyomatosis. Common complications of intravenous leiomyomatosis include embolization, recurrence of the tumor, and metastasis. Surgery is the mainstay of therapy for intravenous leiomyomatosis.

Historical Perspective

[Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Pathophysiology

Intravenous leiomyomatosis is characterized by the extension into venous channels of histologically benign smooth muscle tumor arising from either the wall of a vessel or from a uterine leiomyoma.
Patients are exclusively female, and the majority are white, premenopausal, and parous.
Intravenous leiomyomatosis should be considered in young women with cardiac symptoms who have a right atrial mass as well as a pelvic mass or who have previously undergone hysterectomy for leiomyoma uterus with intravenous involvement.

Causes

The etiology of intravenous leiomyomatosis is unclear.

Differentiating Intravenous Leiomyomatosis from other Diseases

Intravenous leiomyomatosis must be differentiated from other diseases such as:

Renal malignancies
Sarcoma
Thrombosis of the intravenous catheter

Epidemiology and Demographics

The median age is 45 years, with patients ranging from 26 to 70 years old.
Female are exclusively affected with intravenous leiomyomatosis.

The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

Patients of all age groups may develop [disease name].

[Disease name] is more commonly observed among patients aged [age range] years old.
[Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

[Disease name] affects men and women equally.

[Gender 1] are more commonly affected with [disease name] than [gender 2].
The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

There is no racial predilection for [disease name].

[Disease name] usually affects individuals of the [race 1] race.
[Race 2] individuals are less likely to develop [disease name].

Risk Factors

Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

The majority of patients with [disease name] remain asymptomatic for [duration/years].
Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with [disease name] is approximately [#%].
Common complications of intravenous leiomyomatosis include embolization, recurrence of the tumor, and metastasis.
The tumor is slow growing, and the prognosis is favorable.

Diagnosis

Diagnostic Criteria

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

[criterion 1]
[criterion 2]
[criterion 3]
[criterion 4]

Symptoms

Patients may be asymptomatic or have symptoms of uterine leiomyomas, syncopal episodes, and dyspnea on exertion.

[Disease name] is usually asymptomatic.
Symptoms of [disease name] may include the following:

[symptom 1]
[symptom 2]
[symptom 3]
[symptom 4]
[symptom 5]
[symptom 6]

Physical Examination

Patients with [disease name] usually appear [general appearance].
Physical examination may be remarkable for:

[finding 1]
[finding 2]
[finding 3]
[finding 4]
[finding 5]
[finding 6]

Laboratory Findings

There are no specific laboratory findings associated with [disease name].

A [positive/negative] [test name] is diagnostic of [disease name].
An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

There are no [imaging study] findings associated with [disease name].

[Imaging study 1] is the imaging modality of choice for [disease name].
On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

[Disease name] may also be diagnosed using [diagnostic study name].
Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
[Medical therapy 1] acts by [mechanism of action 1].
Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

Surgery is the mainstay of therapy for [disease name].
[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
[Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

There are no primary preventive measures available for [disease name].

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].